Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

Blood cancers such as leukaemia and lymphoma
Inherited genetic disorders including thalassemia and sickle cell disease
Neurological conditions such as cerebral palsy and brain injury
Immune deficiencies and metabolic disorders
Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

Cerebral Palsy
Thalassemia
Leukaemia
HSV Encephalitis
Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

Families gain access to 1,000,000+ stored cord blood units across the network
Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

Order now Find out more

FamiCord Group releases

Patients

7800+

Expand table
No.	Source	Source type	Diagnosis	Medical sector	Year of application	Therapy	Country	Age of the recipient
7901	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	68
7902	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	63
7903	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	57
7904	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	68
7905	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	56
7906	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	61
7907	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	55
7908	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	64
7909	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	64
7910	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	52
7911	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	55
7912	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	67
7913	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	49
7914	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	56
7915	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	47
7916	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	53
7917	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	58
7918	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	49
7919	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	69
7920	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	61
7921	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	54
7922	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	65
7923	Apheresis	Autologous	Multiple Myeloma	Hematology	2016	Standard Therapy	Germany	48
7924	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	60
7925	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	56
7926	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	50
7927	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	73
7928	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	47
7929	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	67
7930	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	62
7931	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	61
7932	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	68
7933	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	65
7934	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	15
7935	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	52
7936	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	20
7937	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	60
7938	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	9
7939	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	61
7940	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	63
7941	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	15
7942	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	37
7943	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	59
7944	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	62
7945	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	58
7946	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	69
7947	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Poland	66
7948	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Germany	67
7949	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2016	Standard Therapy	Germany	57
7950	Apheresis	Allogeneic	Myelodysplastic Syndrome – Rcmd	Hematology	2016	Standard Therapy	Poland	32
7951	Apheresis	Allogeneic	Myelodysplastic Syndrome – Raeb	Hematology	2016	Standard Therapy	Poland	56
7952	Apheresis	Allogeneic	Myelofibrosis	Hematology	2016	Standard Therapy	Poland	72
7953	Apheresis	Allogeneic	Myelofibrosis	Hematology	2016	Standard Therapy	Poland	66
7954	Apheresis	Allogeneic	Myelofibrosis	Hematology	2016	Standard Therapy	Poland	67
7955	Apheresis	Allogeneic	Myeloma Multiplex	Hematology	2016	Standard Therapy	Poland	63
7956	Apheresis	Allogeneic	Myeloma Multiplex	Hematology	2016	Standard Therapy	Poland	51
7957	Apheresis	Allogeneic	Myeloma Multiplex	Hematology	2016	Standard Therapy	Poland	38
7958	Apheresis	Allogeneic	Myeloproliferative Syndrome	Hematology	2016	Standard Therapy	Poland	52
7959	Apheresis	Allogeneic	Myeloproliferative Syndrome	Hematology	2016	Standard Therapy	Germany	63
7960	Apheresis	Autologous	Neuroblastoma	Hematology	2016	Standard Therapy	Germany	5
7961	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	45
7962	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	70
7963	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	43
7964	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	69
7965	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	28
7966	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	1
7967	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	30
7968	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	71
7969	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	58
7970	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	17
7971	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	59
7972	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	58
7973	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	55
7974	Apheresis	Allogeneic	No Data	no data	2016	Standard Therapy	Poland	44
7975	Apheresis	Allogeneic	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Poland	38
7976	Apheresis	Allogeneic	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Poland	58
7977	Apheresis	Allogeneic	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Poland	32
7978	Apheresis	Allogeneic	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Poland	39
7979	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Germany	61
7980	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Germany	73
7981	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Germany	27
7982	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Germany	65
7983	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2016	Standard Therapy	Germany	61
7984	Apheresis	Allogeneic	Plasma Cell Disorder	Hematology	2016	Standard Therapy	Poland	47
7985	Apheresis	Autologous	Plasmacytoma	Hematology	2016	Standard Therapy	Germany	58
7986	Apheresis	Autologous	Plasmacytoma	Hematology	2016	Standard Therapy	Germany	68
7987	Apheresis	Autologous	Plasmacytoma	Hematology	2016	Standard Therapy	Germany	48
7988	Apheresis	Autologous	Primary Central Nervous System Lymphoma	Hematology	2016	Standard Therapy	Germany	62
7989	Apheresis	Autologous	Primary Central Nervous System Lymphoma	Hematology	2016	Standard Therapy	Germany	51
7990	Apheresis	Autologous	Primary Central Nervous System Lymphoma	Hematology	2016	Standard Therapy	Germany	62
7991	Apheresis	Allogeneic	Primary Immunodeficiency	Hematology	2016	Standard Therapy	Poland	5
7992	Apheresis	Allogeneic	Primary Myelofibrosis	Hematology	2016	Standard Therapy	Poland	50
7993	Apheresis	Allogeneic	Primary Myelofibrosis	Hematology	2016	Standard Therapy	Poland	67
7994	Apheresis	Allogeneic	Primary Myelofibrosis	Hematology	2016	Standard Therapy	Poland	67
7995	Apheresis	Allogeneic	Primary Myelofibrosis	Hematology	2016	Standard Therapy	Germany	56
7996	Apheresis	Allogeneic	Primary Myelofibrosis	Hematology	2016	Standard Therapy	Germany	58
7997	Apheresis	Allogeneic	Refractory Anemia With Excess Blasts	Hematology	2016	Standard Therapy	Poland	62
7998	Apheresis	Allogeneic	Severe Aplastic Anemia / Amyloidosis	Hematology	2016	Standard Therapy	Poland	45
7999	Apheresis	Allogeneic	Secondary Acute Myeloid Leukemia At Myeloproliferative Syndrome	Hematology	2016	Standard Therapy	Germany	28
8000	Apheresis	Allogeneic	Severe Aplastic Anemia	Hematology	2016	Standard Therapy	Poland	18

Page 80 of 89 1 78 79 80 81 82 89

Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

100% infusion success rate

For samples released for transplant.

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

Expand table
Sample release date	Medical condition	Recipient relationship	Age of the recipient	Unit volume	Medical center	Country
2005.11	Thalassemia	Allogeneic (Sibling)	4 Years	144ml	Mount Vernon Hospital	Singapore
2005.11	Leukaemia	Allogeneic (Sibling)	Restricted	Restricted	Stem Cells and Immunology Department, Birmingham	UK
2007.02	Thalassemia	Allogeneic (Sibling)	7 Years	76ml	Kinderlink der Tu Munchen	Germany
2009.08	Cerebral Palsy	Autologous (Self)	3 Years	51ml	Duke University, North Carolina	USA
2010.01	Cerebral Palsy	Autologous (Self)	3 Years	81ml	Duke University, North Carolina	USA
2013.10	Thalassemia	Allogeneic (Sibling)	5 Years	58ml	Catherine Lewis Centre, Hammersmith	UK
2014.01	Leukaemia	Allogeneic (Sibling)	4 Years	71ml	Medizinische Hochschule, Hanover	Germany
2014.05	Cerebral Palsy	Autologous (Self)	1 year	68ml	Duke University, North Carolina	USA
2014.06	HSV Encephalitis & NMDA Receptor Antibody Virus	Autologous (Self)	2 Years	57ml	Duke University, North Carolina	USA
2014.08	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	3 Months	39ml	Duke University, North Carolina	USA
2015.02	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	6 Months	53ml	Duke University, North Carolina	USA
2015.03	Severe Combined Immune Deficiency	Autologous (Self)	3 Months	74ml	Duke University, North Carolina	USA
2015.03	Sickle Cell Disease	Allogeneic (Sibling)	2 .5 Years	57ml	BLK Hospital, New Delhi	India
2015.11	Thalassemia	Allogeneic (Sibling)	12 Years	87ml	Children’s Hospital of Pittsburgh of UPMC	USA
2016.03	Cerebral Palsy	Allogeneic (Sibling)	6 Years	101ml	Duke University, North Carolina	USA
2017.04	Lymphoblastic Leukaemia (^1)	N/A (Identical twin girls)	Restricted	125ml	Bambin Gesu Childrens’ Hospital, Rome	Italy
2017.06	Cerebral Palsy	Autologous (Self)	7 Years	82ml	Duke University, North Carolina	USA
2017.06	Cerebral Palsy	Autologous (Self)	3.4 Years	132ml	Duke University, North Carolina	USA
2018.03	Autism	Autologous (Self)	5.4 Years	73ml	Duke University, North Carolina	USA
2018.03	Cerebral Palsy	Autologous (Self)	3.4 years	132ml	Duke University, North Carolina	USA
2019.06	Cerebral Palsy	Allogeneic (Sibling)	3 Years	104ml	Duke University, North Carolina	USA
2022.02	Cerebral Palsy	Allogeneic (Sibling)	11 Years	185ml	Duke University, North Carolina	USA
2023.08	Cerebral Palsy	Allogeneic (Sibling)	3 Years	46ml	Duke University, North Carolina	USA
2024.01	Thalassaemia	Allogeneic (Sibling)	8 Years	45ml	Cincinnati Children’s Hospital Medical Center	USA